Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 24, 2025
Reporting period
Not applicable
Filed with the SEC
Oct 25, 2025
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-25-039331
Filed / recorded
Oct 25, 2025, 1:05 AM UTC
Added to OQRO
Oct 6, 2026, 9:54 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ADMA BIOLOGICS, INC.
Issuer CIK
1368514
Ticker
ADMA
Reporting person
Adam S Grossman
Relationship
Director, Officer
Officer title
President and CEO
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Oct 24, 2025
Transaction code
M
Shares / units
15,000
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
750,950
Ownership form
Direct
Amendment
No
Footnotes from the filing
Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.
The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.